Document 0793
 DOCN  M95A0793
 TI    Poxvirus-based vaccine candidates for cancer, AIDS, and other infectious
       diseases.
 DT    9510
 AU    Perkus ME; Tartaglia J; Paoletti E; Virogenetics Corporation, Rensselaer
       Technology Park, Troy, NY; 12180, USA.
 SO    J Leukoc Biol. 1995 Jul;58(1):1-13. Unique Identifier : AIDSLINE
       MED/95341166
 AB    Over the past 12 years, the poxvirus vector technology has provided
       scientists with valuable reagents to achieve high-level expression of
       proteins, to address questions of structure-function relationship of
       specific polypeptides, to investigate the immunobiology of specific
       pathogens, and to develop recombinant vaccine candidates. It is this
       last role that has drawn enthusiasm from the medical community because
       of the potential this technology has to provide novel approaches for
       addressing urgent needs in human and veterinary medicine. From one
       perspective, the safety issues surrounding the use of vaccinia-based
       vaccine candidates have been addressed with the development of the NYVAC
       and ALVAC vectors. Evaluation of these novel poxvirus vectors are in
       progress to determine their potential impact on cancer and infectious
       disease.
 DE    Acquired Immunodeficiency Syndrome/*PREVENTION & CONTROL/*THERAPY
       Animal  Communicable Disease Control/*METHODS  Human  HIV-1/IMMUNOLOGY
       Immunotherapy  Measles/PREVENTION & CONTROL  Neoplasms/*THERAPY  Poultry
       Diseases/*PREVENTION & CONTROL  Poxviridae/*IMMUNOLOGY  Rabies/THERAPY
       *Vaccines, Synthetic  *Viral Vaccines  JOURNAL ARTICLE  REVIEW  REVIEW,
       ACADEMIC

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).